Navigation Links
Ceres and Texas A&M to develop and market high-biomass sorghum for biofuels
Date:10/5/2007

ment, Ceres and TAES will work together to expand their marker-assisted breeding efforts. Markers allow plant breeders to identify useful traits in seed tissue or when plants are still seedlings. Large numbers of markers provide a roadmap of the sorghum genome, cutting years off development timelines for new products, and making it easier to improve the makeup of the plants to facilitate processing.

"Markers and biotechnology will be crucial for developing sorghum for cellulosic biofuels," says Rooney.

Mascia said Ceres has Texas-sized expectations for the collaboration. "When we combine their resources with our high-throughput trait development capabilities, we believe we can double the rate of improvement to biomass yields, while expanding the range of the crop for earlier planting in cooler and drier conditions, especially on so-called marginal or unproductive land," said Mascia.

He expects that commercial quantities of the initial hybrids will be available in time to meet the requirements of the first cellulosic biorefineries currently being planned.

As part of this agreement, Ceres will obtain exclusive commercialization rights to TAES's high biomass sorghum hybrids developed in the joint research program. The TAES program will receive royalties as well as financial and technology support from Ceres. Other aspects of the collaboration were not disclosed.

"This agreement between Ceres and TAES is a great model of how research institutions and the private sector can collaborate to accelerate existing research programs to solve our country's future energy needs," said Dr. Mark Hussey, director of TAES. "Having our scientists work jointly on future bioenergy research is a win-win situation for both TAES and Ceres, and will help meet the growing demand for biofuels through the development of cellulosic feedstocks."


'/>"/>

Contact: Jason Cook
jason.cook@tamu.edu
979-862-7346
Texas A&M University - Agricultural Communications
Source:Eurekalert

Page: 1 2

Related biology news :

1. Sugar beet virus mutation requires Texas touch
2. Research suggests fitness of Florida panthers improved by limited breeding with Texas animals
3. Texas scientists discover how a hepatitis C protein promotes liver cancer
4. Fire ant-attacking fly spreading rapidly in Texas
5. A much-needed shot in the arm for HIV vaccine development
6. Clam embryo study shows pollutant mixture adversely affects nerve cell development
7. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
8. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
9. Scientists develop new color-coded test for protein folding
10. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
11. Development of portable infectious disease detector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)UVALDE Dr. Daniel Leskovar, a Texas AgriLife Research plant physiologist at the Texas AgriLife Research and Extension Center in Uvalde, has been investigating ways to help vegetable plants make a les
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How to read brain activity? 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court Ordered Meeting of Shareholders 50160 1Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court Ordered Meeting of Shareholders 50160 2Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 50156 1Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 50156 2Immucor Responds To FDA Notice 12802 1Immucor Responds To FDA Notice 12802 2
... signs of spring, like budding trees, are worth ce...mergence of fertile, winged termites swarming furi... them. , In New Orleans, as the swirling, airborn...archers with the Agricultural Research Service (AR...omeday knock down large numbers of Formosan subter...
...r imaging technologies allow physicians to visuali...tecting small blood clots not previously seen, but...,s outcome, a new study suggests. , The study incl...m. About half of the patients (98) had a multidete...gle-detector CT examination. The radiology examina...
...School of Medicine scientists have created the fir... possibly prevent the onset of a brain disease in ...indings, published online this week in the journal...velopment of a vaccine to prevent a group of fatal...cles called prions. , Although no cure for these d...
Other Biology News:Fungus Effective Against Winged Termites 2Newer imaging techniques may lead to over-treatment 2Active Vaccine Prevents Mice From Developing Prion Disease 2Active Vaccine Prevents Mice From Developing Prion Disease 3
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
...hows naturally occurring antibodies contained in, ...for Alzheimer,s disease, CHICAGO, April 15 The U...axter International Inc. (NYSE: BAX ) today,annou...tural antibodies,contained in GAMMAGARD LIQUID [Im... as KIOVIG in the European Union, a plasma-derived...
.../PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(...sentation by Dr.,Chandini Thirukkumaran of the Tom... Multiple Myeloma with Oncolytic Viral Therapy" wa...Cancer Research (AACR) Annual,Meeting. The meeting...,12-16, 2008., The presentation covered preclinic...
... CryoPort, Inc. (OTC,Bulletin Board: CYRX) (http...ent,community through their personal profile on My...he dynamic profile will include interviews with co...ent, and links to recent press., Visit CryoPort,.../profile.php?ID=19849 . Stay updated about CryoPo...
Other Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting 2CryoPort Creates Personal Wall on Wallst.net's Financial Social Community, my.wallst.net 2
GIBCO Dulbecco's Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
Rabbit Anti-LSD1 / BHC110 Antibody, Unconjugated from Upstate
Dulbecco's Phosphate-Buffered Saline (D-PBS) powder from Invitrogen
Rabbit Anti-CUGBP2 Monoclonal Antibody, Unconjugated, Clone PADZMD.495 from Invitrogen
Biology Products: